

CATALYST PHARMACEUTICALS, INC.  
Form 8-K  
June 24, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**  
**THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of Earliest Event Reported): June 23, 2016**

**CATALYST PHARMACEUTICALS, INC.**

**(Exact Name Of Registrant As Specified In Its Charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-33057**  
**(Commission**  
  
**File Number)**

**76-0837053**  
**(I.R.S. Employer**  
  
**Identification No.)**

**355 Alhambra Circle**

**Suite 1250**

**Coral Gables, Florida**  
**(Address of principal executive**  
**offices)**

**33134**  
**(Zip Code)**

**Registrant's telephone number, including area code: (305) 420-3200**

**Not Applicable**

**Former Name or Former address, if changed since last report**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 23, 2016, Catalyst Pharmaceuticals, Inc. ( Company ) and its Chairman, President and Chief Executive Officer, Patrick J. McEnany, entered into an amendment to Mr. McEnany s employment agreement with the Company extending the term of such agreement for an additional two year period. Mr. McEnany s employment agreement with the Company now expires on November 8, 2018. All of the other terms of Mr. McEnany s employment agreement with the Company remain the same.

A copy of Amendment No. 5 to Mr. McEnany s employment agreement with the Company is attached hereto as Exhibit 10.1 and is incorporated herein by reference. The description of Amendment No. 5 that is set forth above is qualified in its entirety by reference to such amendment.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

10.1 Amendment No. 5 to Employment Agreement between the Company and Patrick J. McEnany, dated June 23, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Catalyst Pharmaceuticals, Inc.**

By: /s/ Patrick J. McEnany  
Patrick J. McEnany  
President, Chairman and CEO

Dated: June 24, 2016